EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)

Eine Real-World-Pharmakovigilanzanalyse von Eslicarbazepinacetat anhand der FDA Adverse Events Reporting System (FAERS)-Datenbank von 2013 (Q4) bis 2024 (Q1)

Huafei Tang, Jing Xu, Xian Zhang, Chunliang Chen, Ge Song, Rui Ma, Jinjing Zhao, Qiang Zhao

Frontiers in Pharmacology · 20.09.2024 · 15

DOI: 10.3389/fphar.2024.1463560 ↗

Auf einen Blick

In FAERS wurden 5.719 AE-Meldungen zu Eslicarbazepinacetat ausgewertet. Signale betrafen u. a. Nervensystemstörungen sowie schwere Hautreaktionen.

Fragestellung

Welche unerwünschten Ereignisse sind in FAERS mit Eslicarbazepinacetat assoziiert?

Methode

Auswertung der FAERS-Daten von 2013Q4 bis 2024Q1 mit ROR, PRR, BCPNN und MGPS; Signale mussten alle 4 Algorithmen erfüllen. Zusätzliche Analysen zu Demografie, Zeit bis zum Auftreten und DME.

Ergebnisse

5.719 AE-Meldungen und 1.907 berichtete Fälle. Signifikante SOC-Signale u. a. bei Nervensystemstörungen; 86 disproportionale Preferred Terms. Die meisten AEs traten im ersten Monat auf.

Schlussfolgerung der Autor:innen

Die Studie erweitert das Sicherheits- und Verträglichkeitsprofil von ESL, weist aber darauf hin, dass die klinische Anwendung wegen des AE-Risikos aufmerksam erfolgen sollte, besonders bei Dermatitis exfoliativa und Stevens-Johnson-Syndrom.

Kernaussagen

  • 5.719 AE-Meldungen und 1.907 berichtete Fälle
  • 86 signifikante Preferred Terms
  • Besondere Signale: Dermatitis exfoliativa, Stevens-Johnson-Syndrom, DRESS

Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 20.09.2024. Verfasst von Huafei Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The 305 Hospital of PLA, Beijing, China. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

Auf einen BlickAbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The approval of eslicarbazepine acetate (ESL) by the Food and Drug Administration (FDA) in 2013 marked an advancement in the treatment of adult patients with partial-onset seizures. However, there still remains a paucity of real-world studies regarding the adverse events (AEs) associated with this compound. The principal aim of the present study was to scrutinize ESL-related AEs by leveraging data from the US Food and Drug Administration Adverse Event Reporting System (FAERS) database.

Methods

By extracting all available data since the FDA approval of ESL (2013Q4-2024Q1), disproportionality analysis was performed using reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi-item gamma Poisson shrinker (MGPS) algorithms. AE signals that simultaneously met the requirements of all four algorithms were identified as significant positive signals. Demographic information, time of onset and gender-specific signal detection were also examined. In addition, a special screening process for designated medical events (DME) was implemented to focus on the evaluation and comparison of safety signals within DME and System Organ Classification (SOC) level, as well as SMQ (Standardised MedDRA Queries) level. Stratified analysis by logistic regression is employed to examine the variations across different gender (male and female) and age groups (<18 years old, 18–64 years old, >65 years old).

Results

A total of 5,719 AE reports and 1,907 reported cases were obtained. ESL related AEs were identified in relation to 27 SOCs, among which the significant positive SOCs were nervous system disorders, injury poisoning and procedural complications, etc. There were 86 severely disproportional preferred terms that complied with the four algorithms. Most AEs occurred within the first month after treatment. According to the 86 valuable positive signals with DME screening results, 3 signals of dermatitis exfoliative, stevens-johnson syndrome, drug reaction with eosinophilia and systemic symptoms were consistent with PT signals on the DME-list, with the 3 PTs focusing on skin and subcutaneous tissue disorders and hypersensitivity. Males are more commonly affected by seizures than females. Seizures, hyponatremia, and confusional states were more frequently observed in the elderly population, while aggression, irritability, DRESS (drug reaction with eosinophilia and systemic symptoms), and abnormal behavior were found to be more common in the pediatric population. Both the children and elderly groups exhibited a higher proportion of agitation than the adult group.

Conclusion

Our research enhances the safety and tolerability profile of ESL, but the clinical use of ESL should be noticed and avoided in relation to AEs since it raises the risk of dermatitis exfoliative, stevens-johnson syndrome. Particular attention should be paid to DRESS in children and hyponatremia in the elderly.

Schlagwörter

Stichwörter der Autor:innen

AESESLFDAeslicarbazepine acetatepharmacovigilance analysis

Autor:innen und Institutionen

  • Department of Pharmacy, The 305 Hospital of PLA, Beijing, China.
  • Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing, China.
  • Department of Neurology, The 305 Hospital of PLA, Beijing, China.

Zitieren

APA

Tang, H., Xu, J., Zhang, X., Chen, C., Song, G., Ma, R., Zhao, J., & Zhao, Q. (2024). A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1). Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1463560

Vancouver

Tang H, Xu J, Zhang X, Chen C, Song G, Ma R, et al. A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1). Frontiers in Pharmacology. 2024;15. doi:10.3389/fphar.2024.1463560

BibTeX
@article{Tang2024,
  author = {Tang, Huafei and Xu, Jing and Zhang, Xian and Chen, Chunliang and Song, Ge and Ma, Rui and Zhao, Jinjing and Zhao, Qiang},
  title = {A real-world pharmacovigilance analysis of eslicarbazepine acetate using the FDA adverse events reporting system (FAERS) database from 2013 (Q4) to 2024 (Q1)},
  journal = {Frontiers in Pharmacology},
  year = {2024},
  volume = {15},
  doi = {10.3389/fphar.2024.1463560}
}
Kostenlos starten →